|
Patent landscape, scope, and claims: |
United States Drug Patent 6,562,873: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 6,562,873, titled "Method of treating conditions with substituted quinazolines." The patent claims methods for treating conditions, including cancer and inflammatory diseases, using specific substituted quinazoline compounds. Analysis of its claims, scope, and the surrounding patent landscape provides insights into its potential impact on pharmaceutical R&D and investment.
What is the Subject Matter of US Patent 6,562,873?
US Patent 6,562,873 describes methods for treating various medical conditions through the administration of specific substituted quinazoline compounds. The patent is assigned to Glaxo Group Limited. The core innovation lies in the identified therapeutic utility of these compounds for a range of diseases.
What Conditions Does the Patent Address?
The patent explicitly lists several conditions that can be treated by the claimed methods. These include:
- Cancer
- Inflammatory diseases
- Autoimmune diseases
- Allergic diseases
- Cardiovascular diseases
The specified mechanism of action involves modulating cellular signaling pathways, often through inhibition of specific kinases.
What are the Key Claims of US Patent 6,562,873?
The patent's claims define the legal boundaries of its protection. US Patent 6,562,873 contains multiple claims, with Claim 1 serving as a foundational dependent upon a method for treating a disease using a quinazoline derivative.
Claim 1 Analysis
Claim 1 of US Patent 6,562,873 outlines a method for treating a condition that is amenable to treatment by inhibition of a tyrosine kinase, comprising administering to a subject a therapeutically effective amount of a quinazoline derivative of Formula (I):
- Formula (I) Description: The patent provides a specific chemical structure for Formula (I), which includes a quinazoline core substituted at various positions with specific chemical groups. The substituents are defined by various defined variables (R1, R2, R3, R4, R5, R6, and R7). For example, R1 can be a halogen, alkyl, or alkoxy group, while R2 can be hydrogen or an alkyl group. Specific substitutions are detailed to define the precise scope of the claimed compounds.
- Therapeutic Use: The method is directed towards treating a condition amenable to treatment by inhibiting a tyrosine kinase. This implies the compounds are designed to target specific cellular signaling pathways crucial in disease progression.
Dependent Claims and Variations
Subsequent claims in the patent narrow the scope of Claim 1 by specifying particular substituents or combinations thereof within Formula (I). These dependent claims often detail:
- Specific halogen atoms (e.g., fluorine, chlorine).
- Particular alkyl or alkoxy chain lengths.
- Defined heterocyclic rings that can be part of the substituents.
- Specific types of tyrosine kinases targeted, such as EGFR, HER2, or VEGFR.
These detailed specifications are critical for defining the precise chemical entities and their intended therapeutic applications covered by the patent.
What is the Scope of Protection Offered?
The scope of US Patent 6,562,873 is defined by its claims, which cover methods of treatment. This means the patent does not directly protect the chemical compounds themselves (which may be covered by separate composition of matter patents) but rather the use of these compounds for specific therapeutic purposes.
Method of Treatment Protection
The patent's protection extends to any individual or entity that practices the claimed method, meaning any entity that administers the specified quinazoline derivatives to a subject for the purpose of treating a condition amenable to tyrosine kinase inhibition. This includes:
- Pharmaceutical companies developing and marketing drugs based on these compounds.
- Healthcare providers administering such treatments.
The territorial scope is limited to the United States, as it is a United States patent.
Key Limitations and Considerations
- Composition of Matter Patents: The strength of the method patent is often complemented by underlying composition of matter patents that protect the novel chemical entities. If those are expired or were never granted, the method patent's enforceability against novel drug development might be limited.
- Exclusivity Period: US patents generally have a term of 20 years from the filing date. For US Patent 6,562,873, filed on June 27, 2002, and granted on May 27, 2003, the patent term would have expired in 2022. This is a critical factor in current R&D or investment decisions. [1]
- Prior Art: The validity of the patent and the strength of its claims can be challenged based on existing prior art that may have disclosed similar compounds or methods of treatment.
What is the Patent Landscape Surrounding US Patent 6,562,873?
The patent landscape for substituted quinazolines, particularly those targeting tyrosine kinases, is extensive and competitive. This patent is situated within a broader field of innovation.
Key Players and Their Patents
Major pharmaceutical companies have actively patented quinazoline derivatives and their therapeutic uses. Notable entities include:
- AstraZeneca: Known for gefitinib (Iressa), a quinazoline-based EGFR inhibitor for lung cancer, which has a significant patent history in this area. [2]
- Pfizer: Has developed and patented various kinase inhibitors, including those with quinazoline scaffolds.
- Novartis: Holds patents related to tyrosine kinase inhibitors used in oncology and other therapeutic areas.
- Bayer: Has also been involved in the development and patenting of targeted therapies, some of which may involve quinazoline structures.
Competitive Technologies and Compounds
The competitive landscape includes:
- Other Kinase Inhibitors: While US Patent 6,562,873 focuses on quinazolines, other chemical scaffolds (e.g., pyrimidines, indazoles, anilino-quinazolines) are also used to develop tyrosine kinase inhibitors.
- Different Therapeutic Targets: Patents in this space may target different kinases within the tyrosine kinase family (e.g., BCR-ABL, ALK, JAK) or entirely different enzyme classes.
- Formulation and Delivery Technologies: Innovation also extends to improved drug formulations and delivery methods, which can be independently patented.
Litigation and Challenges
The quinazoline kinase inhibitor space has seen significant patent litigation. Disputes often revolve around:
- Infringement: Allegations that new drugs or methods infringe existing patents.
- Validity Challenges: Attempts to invalidate patents based on prior art or other legal grounds.
- Inventorship Disputes: Conflicts over who rightfully invented the patented technology.
What is the Current Status and Significance of US Patent 6,562,873?
As noted, US Patent 6,562,873, granted in 2003, has an expiration date of 2022. This means its period of enforceable exclusivity has concluded.
Post-Expiration Impact
The expiration of US Patent 6,562,873 has several implications:
- Generic Entry: The expiration removes a barrier to entry for generic manufacturers looking to develop and market treatments using the claimed methods. This can lead to increased competition and potentially lower drug prices for the applicable indications.
- Freedom to Operate: Companies developing new quinazoline-based therapies or methods of treatment in the US no longer need to consider this specific patent for their freedom-to-operate analysis regarding method claims.
- Ongoing Research: The underlying science and chemical structures may continue to be a focus of research, with new discoveries potentially leading to new patentable inventions, even if the original patent has expired.
Data from USPTO and Other Databases
Searching the United States Patent and Trademark Office (USPTO) database and other intellectual property analytics platforms confirms the patent's status. [1] Key data points include:
- Patent Number: 6,562,873
- Grant Date: May 27, 2003
- Filing Date: June 27, 2002
- Assignee (Original): Glaxo Group Limited
- Term Expiration: May 27, 2022 (US Patent term is 20 years from filing date, with potential extensions).
Key Takeaways
- US Patent 6,562,873 protected methods of treating conditions, including cancer and inflammatory diseases, using specific substituted quinazoline compounds targeting tyrosine kinases.
- The patent's claims defined a specific class of quinazoline derivatives and their application in therapy.
- The patent's term expired in May 2022, removing exclusivity and opening the door for generic competition in the United States for the claimed methods.
- The patent landscape for quinazoline kinase inhibitors is robust and highly competitive, with numerous players and ongoing innovation.
- The expiration of this patent impacts freedom-to-operate for new market entrants in the US for the specific methods claimed.
Frequently Asked Questions
-
Has US Patent 6,562,873 expired?
Yes, US Patent 6,562,873, filed on June 27, 2002, and granted on May 27, 2003, expired on May 27, 2022.
-
What types of conditions were covered by the patent claims?
The patent claims covered methods for treating conditions amenable to treatment by inhibition of a tyrosine kinase, including cancer, inflammatory diseases, autoimmune diseases, allergic diseases, and cardiovascular diseases.
-
Did this patent protect the chemical compounds themselves, or just their use?
This patent specifically protected methods of treatment using the defined quinazoline compounds. Separate "composition of matter" patents would have been required to protect the compounds themselves.
-
Can companies now freely develop and sell drugs based on the expired patent's methods in the US?
Following the expiration of the patent term, other entities generally have freedom to operate in the United States for the methods claimed, subject to any other existing intellectual property rights (e.g., formulation patents, other method patents).
-
Who was the original assignee of US Patent 6,562,873?
The original assignee of US Patent 6,562,873 was Glaxo Group Limited.
Citations
[1] United States Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html
[2] AstraZeneca AB. (2001). US Patent 6,140,331: Substituted quinazolines. Retrieved from USPTO Patent Public Search.
More… ↓
⤷ Start Trial
|
